Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
08 02 2019
Historique:
received: 17 10 2018
revised: 28 11 2018
pubmed: 14 12 2018
medline: 27 6 2019
entrez: 15 12 2018
Statut: ppublish

Résumé

The interaction between the receptor 4-1BB and its ligand 4-1BBL provides co-stimulatory signals for T-cell activation and proliferation. However, differences in the mouse and human molecules might result in differential engagement of this pathway. Here, we report the crystal structure of mouse 4-1BBL and of the mouse 4-1BB/4-1BBL complex, which together provided insights into the molecular mechanism by which m4-1BBL and its cognate receptor recognize each other. Unlike all human or mouse tumor necrosis factor ligands that form noncovalent and mostly trimeric assemblies, the m4-1BBL structure formed a disulfide-linked dimeric assembly. The structure disclosed that certain differences in the amino acid composition along the intramolecular interface, together with two specific residues (Cys-246 and Ser-256) present exclusively in m4-1BBL, are responsible for this unique dimerization. Unexpectedly, upon m4-1BB binding, m4-1BBL undergoes structural changes within each protomer; moreover, the individual m4-1BBL protomers rotate relative to each other, yielding a dimerization interface with more inter-subunit interactions. We also observed that in the m4-1BB/4-1BBL complex, each receptor monomer binds exclusively to a single ligand subunit with contributions of cysteine-rich domain 1 (CRD1), CRD2, and CRD3. Furthermore, structure-guided mutagenesis of the binding interface revealed that novel binding interactions with the GH loop, rather than the DE loop, are energetically critical and define the m4-1BB receptor selectivity for m4-1BBL. A comparison with the human 4-1BB/4-1BBL complex highlighted several differences between the ligand- and receptor-binding interfaces, providing an explanation for the absence of inter-species cross-reactivity between human and mouse 4-1BB and 4-1BBL molecules.

Identifiants

pubmed: 30545939
pii: S0021-9258(20)36832-0
doi: 10.1074/jbc.RA118.006297
pmc: PMC6369289
doi:

Substances chimiques

4-1BB Ligand 0
Multiprotein Complexes 0
TNFRSF9 protein, human 0
Tumor Necrosis Factor Receptor Superfamily, Member 9 0

Banques de données

PDB
['6D3N', '6MKB', '6MKZ', '5WI8']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1831-1845

Subventions

Organisme : NIGMS NIH HHS
ID : P41 GM103393
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI110929
Pays : United States

Informations de copyright

© 2019 Bitra et al.

Références

J Biol Chem. 2018 Jan 26;293(4):1317-1329
pubmed: 29242193
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
PLoS One. 2011 Jan 14;6(1):e16129
pubmed: 21264248
Mol Cell Biol. 1998 Jan;18(1):558-65
pubmed: 9418902
J Immunol. 1998 Mar 1;160(5):2488-94
pubmed: 9498794
PLoS One. 2014 Jan 21;9(1):e86337
pubmed: 24466035
Trends Biochem Sci. 2002 Jan;27(1):19-26
pubmed: 11796220
Eur J Immunol. 2016 Mar;46(3):513-22
pubmed: 26773716
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19452-7
pubmed: 18040044
Cell. 2001 Feb 23;104(4):487-501
pubmed: 11239407
Eur J Immunol. 2008 Apr;38(4):1024-32
pubmed: 18395851
Eur J Immunol. 1994 Feb;24(2):367-74
pubmed: 8299685
Semin Immunol. 1998 Dec;10(6):481-9
pubmed: 9826581
J Biol Chem. 2018 Jun 29;293(26):9958-9969
pubmed: 29720398
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):641-5
pubmed: 18178614
Methods Enzymol. 2003;374:229-44
pubmed: 14696376
Trends Biochem Sci. 1998 Feb;23(2):74-9
pubmed: 9538693
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
J Immunol. 2015 Jan 1;194(1):134-41
pubmed: 25404362
EMBO J. 1999 Apr 15;18(8):2119-26
pubmed: 10205166
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):133-44
pubmed: 20124693
Immunol Rev. 2009 May;229(1):356-86
pubmed: 19426233
J Immunol. 1993 Feb 1;150(3):771-81
pubmed: 7678621
J Exp Med. 2014 Jun 30;211(7):1433-48
pubmed: 24958847
Acta Crystallogr D Biol Crystallogr. 2003 Jul;59(Pt 7):1131-7
pubmed: 12832755
J Biol Chem. 2011 Apr 1;286(13):11226-35
pubmed: 21285457
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1360-6
pubmed: 11567146
Structure. 2006 Aug;14(8):1321-30
pubmed: 16905106
J Biol Chem. 2018 Jun 22;293(25):9880-9891
pubmed: 29720399
Mol Cell. 1999 Oct;4(4):563-71
pubmed: 10549288
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):635-40
pubmed: 18182486
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Nat Med. 1997 Jun;3(6):682-5
pubmed: 9176498
J Immunol. 2012 Jul 1;189(1):245-52
pubmed: 22664871
J Biol Chem. 2010 Mar 19;285(12):9202-10
pubmed: 20032458
Immunol Rev. 2011 Nov;244(1):197-217
pubmed: 22017440
J Biol Chem. 2000 Oct 6;275(40):31171-7
pubmed: 10893238

Auteurs

Aruna Bitra (A)

From the Division of Immune Regulation, La Jolla Institute for Immunology (LJI), La Jolla, California 92037.

Tzanko Doukov (T)

the Stanford Synchrotron Radiation Lightsource, SLAC, Menlo Park, California 94025.

Giuseppe Destito (G)

Kirin Kyowa Hakko Pharmaceutical Research, La Jolla, California 92037.

Michael Croft (M)

From the Division of Immune Regulation, La Jolla Institute for Immunology (LJI), La Jolla, California 92037.
the Department of Medicine, University of California San Diego, La Jolla, California 92037, and.

Dirk M Zajonc (DM)

From the Division of Immune Regulation, La Jolla Institute for Immunology (LJI), La Jolla, California 92037, dzajonc@lji.org.
the Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH